Chemotherapy News and Research

Latest Chemotherapy News and Research

Shutting off a critical cancer gene causes cancers in mice to self-destruct

Killing cancerous tumors isn't easy, as anyone who has suffered through chemotherapy can attest.

1 Aug 2007

Interferon alpha and sorafenib combined work better than either alone against kidney cancer

A combination of two drugs works better than either drug alone for patients with renal cell carcinoma, the most common form of kidney cancer, according to a pilot study led by Duke University Comprehensive Cancer Center researchers.

1 Aug 2007

Bone marrow restores fertility in female mice

A new study from Massachusetts General Hospital (MGH) researchers confirms that female mice that receive bone marrow transplantation after fertility-destroying chemotherapy can go on to have successful pregnancies throughout their normal reproductive life.

31 Jul 2007

Good signal for liver tumour therapy

The linking of two signalling pathways in the cells of liver tumours has a clear influence on their malignancy. Activation of the platelet-derived growth factor (PDGF) messenger molecule is decisive for this linking.

30 Jul 2007

GPs antibiotic prescribing practices are still contributing to resistance

GPs are still prescribing antibiotics for up to 80% of cases of sore throat, otitis media, upper respiratory tract infections, and sinusitis, despite the fact that official guidance warns against this practice, according to an analysis of the world's largest primary care database of consultations and prescriptions, published this week in a supplement to the Journal of Antimicrobial Chemotherapy.

26 Jul 2007

High-dose chemotherapy and a stem cell transplant cures testicular cancer

Testicular cancer patients who do not respond to traditional therapy can be cured with high-dose chemotherapy and a stem cell transplant, according to an Indiana University School of Medicine report in the July 26 issue of the New England Journal of Medicine.

26 Jul 2007

White blood cell booster may help cancer patients avoid deadly complications

Cancer patients who receive a drug that stimulates the growth of infection-fighting white blood cells may be significantly less likely to die from a chemotherapy-related complication characterized by fever and low white blood cell levels, according to a multi-institutional study led by researchers from the University of Rochester School of Medicine and Dentistry and the Duke University Comprehensive Cancer Center.

26 Jul 2007

FDA advisory committee recommends that FDA wait for overall survival results from Satraplatin phase 3 trial

GPC Biotech AG has announced that the Oncologic Drugs Advisory Committee (ODAC) for the U.S. Food and Drug Administration (FDA) recommended (12-0) that the FDA should wait for the final survival analysis of the SPARC trial before deciding whether the satraplatin application is approvable for the treatment of hormone-refractory prostate cancer patients whose prior chemotherapy has failed.

25 Jul 2007

CTRC enrolls first patients in study for sarcoma

The Cancer Therapy & Research Center Institute for Drug Development, in collaboration with Oncolytics Biotech Inc., a biotechnology company, has enrolled the first two patients in a new Phase II clinical study for patients with various types of sarcomas that have metastasized to the lung.

25 Jul 2007

Adult survivors of childhood leukemia exercise less putting themselves at risk for obesity

Overcoming pediatric cancer may only mark the beginning of a young survivor's lifelong battle to stay healthy.

24 Jul 2007

Sperm freezing for young male cancer patients

A recent study at Hamilton Health Sciences proves that sperm freezing and banking is an effective way to preserve fertility in adolescents and young adult (AYA) males with cancer.

23 Jul 2007

New hope for common form of childhood cancer

Dr. Richard Lock, Head of the Leukaemia Biology Program at the Children's Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.

23 Jul 2007

IDM Pharma plans to amend NDA for Mifamurtide (L-MTP-PE) for the treatment of osteosarcoma

IDM Pharma, Inc. has announced that it has recently met with the U.S. Food and Drug Administration (FDA) and informed the FDA that the Company intends to take immediate action to supplement the data in its current New Drug Application (NDA) for mifamurtide (L-MTP-PE), formerly known as Junovan, which is being reviewed for the treatment of children and adolescents with non-metastatic osteosarcoma.

23 Jul 2007

EpiCept to conduct Phase III study of EpiCept NP-1 for treatment of chemotherapy induced peripheral neuropathy

EpiCept Corporation has announced that it will study EpiCept NP-1, its patented topical cream formulation of two FDA-approved drugs, 4% amitriptyline and 2% ketamine, for the treatment of chemotherapy induced peripheral neuropathy (CPN) in the ATTRACT-CPN Phase III Study (Assessment of Topical Treatment Response with Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy).

23 Jul 2007